Challenges and strategies for clinical treatment of low-level viremia in chronic hepatitis B patients
- VernacularTitle:慢性乙型肝炎患者低病毒血症临床治疗的挑战与策略
- Author:
Huilin GAN
1
;
Cuicui SHI
1
;
Guangming LI
1
Author Information
- Publication Type:Review
- Keywords: Hepatitis B， chronic; Low-Level Viremia; Viral Load; Antiviral Agents
- From: Journal of Clinical Hepatology 2025;41(4):736-741
- CountryChina
- Language:Chinese
- Abstract: Hepatitis B virus （HBV） infection is a global public health issue， affecting the health of 250 million people worldwide. Despite the significant progress in antiviral therapy for HBV， some patients still experience low-level viremia （LLV） after receiving antiviral therapy and fail to achieve viral clearance， with an HBV DNA load remaining at a relatively low level of 20 — 2 000 IU/mL. LLV is often caused by multiple factors such as the high stability of the virus， the difficulty in clearing the virus with antiviral drugs， host immune factors， and drug resistance， which increase the difficulties in antiviral therapy. In addition， LLV can also cause liver damage， which may eventually progress to severe outcomes such as hepatocellular carcinoma. This article reviews LLV in hepatitis B in terms of diagnosis， influencing factors， clinical significance， and treatment strategies.
